The ‘AMBITION' trial, is designed to assess safety, tolerability, and pharmacokinetics of 75 mg CRV431, administered orally to F2 and F3 NASH patients

This article is based on probability, rather than certainty. The author is of the opinion that at some point the two terms become interchangeable....

CRV431 has exerted antifibrotic activity in a number of in vitro and in vivo studies conducted by independent research laboratories

Yesterday marked the 36th year that the world observed World No Tobacco Day. This relatively obscure milestone masks a stalled effort to curb consumption of combustible cigarettes and other nicotine-related products. It’s unlikely most people paid any attention. But the impact of smoking is all around us, even if we don’t see it. Statistics rarely tell a provocative story to compel people to action.